In vitro interaction between amphotericin B and azoles in Candida albicans

Jose Antonio Vazquez, Maria T. Arganoza, Julie K. Vaishampayan, Robert A. Akins

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The use of azole prophylaxis as a measure to prevent invasive fungal infections in high-risk patients is increasing and is now the standard of care in many institutions. Previous studies disagree on whether preexposure of Candida albicans to azoles affects their subsequent susceptibility to amphotericin B (AmB). The present in vitro study indicates that azole exposure generates a subpopulation of cells that are not affected by subsequent exposure to AmB. These cells that are phenotypically resistant to Amb are not stably resistant, but for short periods of exposure, they can tolerate up to 100-fold the level of Amb tolerated by most cells not exposed to azole. The percentage of cells that convert to phenotypic resistance to Amb varies with the concentration and the azole. Itraconazole is more effective than fluconazole in generating cells that are phenotypically resistant to AmB and that tolerate an otherwise lethal transient exposure to AmB. Until cells that are not exposed to fluconazole are simultaneously challenged with AmB, they are not protected to a significant extent from killing by AmB. Cells that are challenged with continuous exposure to AmB also acquire phenotypic resistane to Amb at increased frequencies by azole preexposure, but this requires that the azole be continuously present during incubation with AmB. In addition, Candida cells taken from mature colonies that are not actively growing are not susceptible to the short-term killing effects of Amb without azole preexposure. The adaptive responses of C. albicans to AmB and potentially other antifungal agents that may result from prior exposure to azoles in vitro or potentially in microenvironments in vivo that induce physiological changes may have major clinical implications.

Original languageEnglish (US)
Pages (from-to)2511-2516
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume40
Issue number11
StatePublished - Nov 1 1996
Externally publishedYes

Fingerprint

Azoles
Amphotericin B
Candida albicans
Fluconazole
In Vitro Techniques
Itraconazole
Antifungal Agents
Standard of Care
Candida
B-Lymphocytes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Vazquez, J. A., Arganoza, M. T., Vaishampayan, J. K., & Akins, R. A. (1996). In vitro interaction between amphotericin B and azoles in Candida albicans. Antimicrobial Agents and Chemotherapy, 40(11), 2511-2516.

In vitro interaction between amphotericin B and azoles in Candida albicans. / Vazquez, Jose Antonio; Arganoza, Maria T.; Vaishampayan, Julie K.; Akins, Robert A.

In: Antimicrobial Agents and Chemotherapy, Vol. 40, No. 11, 01.11.1996, p. 2511-2516.

Research output: Contribution to journalArticle

Vazquez, JA, Arganoza, MT, Vaishampayan, JK & Akins, RA 1996, 'In vitro interaction between amphotericin B and azoles in Candida albicans', Antimicrobial Agents and Chemotherapy, vol. 40, no. 11, pp. 2511-2516.
Vazquez, Jose Antonio ; Arganoza, Maria T. ; Vaishampayan, Julie K. ; Akins, Robert A. / In vitro interaction between amphotericin B and azoles in Candida albicans. In: Antimicrobial Agents and Chemotherapy. 1996 ; Vol. 40, No. 11. pp. 2511-2516.
@article{d627c6e99750419694831df23f3a2d35,
title = "In vitro interaction between amphotericin B and azoles in Candida albicans",
abstract = "The use of azole prophylaxis as a measure to prevent invasive fungal infections in high-risk patients is increasing and is now the standard of care in many institutions. Previous studies disagree on whether preexposure of Candida albicans to azoles affects their subsequent susceptibility to amphotericin B (AmB). The present in vitro study indicates that azole exposure generates a subpopulation of cells that are not affected by subsequent exposure to AmB. These cells that are phenotypically resistant to Amb are not stably resistant, but for short periods of exposure, they can tolerate up to 100-fold the level of Amb tolerated by most cells not exposed to azole. The percentage of cells that convert to phenotypic resistance to Amb varies with the concentration and the azole. Itraconazole is more effective than fluconazole in generating cells that are phenotypically resistant to AmB and that tolerate an otherwise lethal transient exposure to AmB. Until cells that are not exposed to fluconazole are simultaneously challenged with AmB, they are not protected to a significant extent from killing by AmB. Cells that are challenged with continuous exposure to AmB also acquire phenotypic resistane to Amb at increased frequencies by azole preexposure, but this requires that the azole be continuously present during incubation with AmB. In addition, Candida cells taken from mature colonies that are not actively growing are not susceptible to the short-term killing effects of Amb without azole preexposure. The adaptive responses of C. albicans to AmB and potentially other antifungal agents that may result from prior exposure to azoles in vitro or potentially in microenvironments in vivo that induce physiological changes may have major clinical implications.",
author = "Vazquez, {Jose Antonio} and Arganoza, {Maria T.} and Vaishampayan, {Julie K.} and Akins, {Robert A.}",
year = "1996",
month = "11",
day = "1",
language = "English (US)",
volume = "40",
pages = "2511--2516",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - In vitro interaction between amphotericin B and azoles in Candida albicans

AU - Vazquez, Jose Antonio

AU - Arganoza, Maria T.

AU - Vaishampayan, Julie K.

AU - Akins, Robert A.

PY - 1996/11/1

Y1 - 1996/11/1

N2 - The use of azole prophylaxis as a measure to prevent invasive fungal infections in high-risk patients is increasing and is now the standard of care in many institutions. Previous studies disagree on whether preexposure of Candida albicans to azoles affects their subsequent susceptibility to amphotericin B (AmB). The present in vitro study indicates that azole exposure generates a subpopulation of cells that are not affected by subsequent exposure to AmB. These cells that are phenotypically resistant to Amb are not stably resistant, but for short periods of exposure, they can tolerate up to 100-fold the level of Amb tolerated by most cells not exposed to azole. The percentage of cells that convert to phenotypic resistance to Amb varies with the concentration and the azole. Itraconazole is more effective than fluconazole in generating cells that are phenotypically resistant to AmB and that tolerate an otherwise lethal transient exposure to AmB. Until cells that are not exposed to fluconazole are simultaneously challenged with AmB, they are not protected to a significant extent from killing by AmB. Cells that are challenged with continuous exposure to AmB also acquire phenotypic resistane to Amb at increased frequencies by azole preexposure, but this requires that the azole be continuously present during incubation with AmB. In addition, Candida cells taken from mature colonies that are not actively growing are not susceptible to the short-term killing effects of Amb without azole preexposure. The adaptive responses of C. albicans to AmB and potentially other antifungal agents that may result from prior exposure to azoles in vitro or potentially in microenvironments in vivo that induce physiological changes may have major clinical implications.

AB - The use of azole prophylaxis as a measure to prevent invasive fungal infections in high-risk patients is increasing and is now the standard of care in many institutions. Previous studies disagree on whether preexposure of Candida albicans to azoles affects their subsequent susceptibility to amphotericin B (AmB). The present in vitro study indicates that azole exposure generates a subpopulation of cells that are not affected by subsequent exposure to AmB. These cells that are phenotypically resistant to Amb are not stably resistant, but for short periods of exposure, they can tolerate up to 100-fold the level of Amb tolerated by most cells not exposed to azole. The percentage of cells that convert to phenotypic resistance to Amb varies with the concentration and the azole. Itraconazole is more effective than fluconazole in generating cells that are phenotypically resistant to AmB and that tolerate an otherwise lethal transient exposure to AmB. Until cells that are not exposed to fluconazole are simultaneously challenged with AmB, they are not protected to a significant extent from killing by AmB. Cells that are challenged with continuous exposure to AmB also acquire phenotypic resistane to Amb at increased frequencies by azole preexposure, but this requires that the azole be continuously present during incubation with AmB. In addition, Candida cells taken from mature colonies that are not actively growing are not susceptible to the short-term killing effects of Amb without azole preexposure. The adaptive responses of C. albicans to AmB and potentially other antifungal agents that may result from prior exposure to azoles in vitro or potentially in microenvironments in vivo that induce physiological changes may have major clinical implications.

UR - http://www.scopus.com/inward/record.url?scp=0029926514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029926514&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 2511

EP - 2516

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -